Related Experiment Video

Updated: Jul 11, 2026

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

[Effect of carvedilol on antioxidative enzymatic defence in patients with stable angina]

Jan Kowalski1, Jan Błaszczyk, Tomasz Cegliński

  • 1Katedra Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej UM w Łodzi.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|September 20, 2007
PubMed

Insights

Carvedilol therapy improved antioxidant defenses in patients with stable angina. The drug increased superoxide dismutase (SOD-1), glutathione peroxidase (GSH-Px), and catalase (CAT) enzyme activities, aiding recovery.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Stable angina patients exhibit diminished antioxidative enzymatic defense.
  • This reduction impacts the body's ability to combat oxidative stress.

Purpose of the Study:

  • To investigate the effect of carvedilol on antioxidative enzymatic defense in stable angina patients.
  • To assess changes in superoxide dismutase (SOD-1), glutathione peroxidase (GSH-Px), and catalase (CAT) activities.

Main Methods:

  • 27 stable angina patients received escalating doses of carvedilol (12.5-50 mg/day).
  • Erythrocyte SOD-1, GSH-Px, and CAT activities were measured pre-therapy and at 4, 8, and 12 weeks.
  • A control group of 12 healthy subjects was included for comparison.

Main Results:

  • Patients with stable angina showed significantly lower SOD-1, GSH-Px, and CAT activities compared to healthy controls.
  • Carvedilol treatment led to a notable increase in all three enzyme activities.
  • GSH-Px levels in patients approached those of healthy subjects after 8 and 12 weeks of therapy.

Conclusions:

  • Carvedilol significantly enhances the antioxidative enzymatic defense system in patients with stable angina.
  • The drug's ability to boost SOD-1, GSH-Px, and CAT suggests a protective role against oxidative stress in this patient group.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...